Obok Casmir’s Post

Who is next? Generative AI platforms drive recent drug discovery dealmaking - check out this article. The potential of generative AI models to accelerate the design of drug candidates looks set to boost the funding raised in recent years by AI-focused companies and is driving dealmaking by major biopharma companies seeking to enhance their pipelines. Will this trend continue? https://lnkd.in/gp65xGhS #biopharma #biotech #lifesciences #generativeai #artificialintelligence #genAI

This week, we dive into the exciting advancements and discussions in AI-driven drug discovery, highlighting the potential and challenges of implementing AI in drug discovery. 🌟 AI's Promising Potential in Drug Discovery Despite the hype and scepticism, AI holds significant promise if used correctly. Key to success are relevant and practical algorithms that generate stable, synthesizable compounds, realistic synthesis routes, and accurate predictive models. AI must show reproducible benefits across diverse projects, supported by compelling evidence. Tools should be robust, scalable, and user-friendly, allowing non-experts to use them easily. Adapting workflows and feeding AI with relevant data can significantly enhance decision-making and benefit drug discovery without replacing skilled chemists. 🏛️ FDA's AI/ML Guidance on the Horizon The FDA plans to release draft guidance on AI/ML in drug development this year. This guidance, driven by feedback and reviews of over 300 AI-related submissions, aims to clarify AI applications from drug target identification to post-market safety surveillance. The focus is on ensuring strong evidence, accessibility, and global regulatory harmonization. 🤝 Merck & Biolojic Design Partner for AI-Driven Therapeutics Merck KGaA, Darmstadt, Germany has partnered with Biolojic Design, Ltd. to develop new oncology and immunology therapeutics using AI, in a deal potentially worth up to 346 million euros. This collaboration focuses on creating multi-specific antibodies and antibody-drug conjugates (ADCs) to block tumour escape mechanisms and enhance safety and efficacy. #AIDDD #AIDrivenDrugDiscovery #DrugDiscovery #AI

All the buzz of AI/ML impact on R&D requires the infrastructure and solutions to ingest and process the data. Benchling is ready to support advanced analytics against the data model within our solutions. Are you ready for AI/ML? Benchling is!!! How can we help you?

Big Pharma is pouring billions into AI, hoping to speed up drug development and drive innovation. But instead of boosting partnerships with biotech, AI-focused biotechs might become more of a competitor to pharma's in-house R&D efforts, according to S&P Global. The pharma-AI market is set to skyrocket from $1 billion in 2022 to nearly $22 billion by 2027. While early AI partnerships with tech giants like Microsoft and IBM helped pharma giants like Pfizer and Novartis, today's AI-driven biotechs are often dependent on Big Pharma for funding and resources. Still, AI is reducing drug development timelines - from four to seven years down to two to three years - especially in fields like oncology and neurology. But while AI holds a lot of promise, it will take years for the full benefits to be realized. Continued investment, adaptability, and change management will be key. #AIinPharma #Biotech #PharmaR&D #Innovation #HealthcareAI #DrugDevelopment #BigPharma

Dr Reddy's arm rolls AI&ML assisted drug discovery platform Aurigene.AI The platform is an end-to-end solution for small molecule drug discovery that will combine AI & ML capabilities with Aurigene's core expertise in synthesising and testing molecules in vitro and in vivo. It has been rolled out with an eye on accelerating drug discovery projects, from hit identification to candidate nomination, Dr Reddy's said on Wednesday. #DrReddys | #DrugDiscoveryProjects | #Aurigenecoreexpertise | #TestingMolecules | #Healthnews Read more:

🚀 Exciting News in Drug Discovery! Isomorphic Labs, the dynamic spinout of Google AI R&D division DeepMind, is making waves with groundbreaking partnerships. 🤝💊 🌐 Isomorphic has sealed strategic deals with pharmaceutical giants Eli Lilly and Company and Novartis, valued at a combined $3 billion! 🤑 This collaboration aims to leverage AI for the discovery of innovative medications to combat various diseases. 🧬💡 🚀 Eli Lilly's partnership involves an upfront payment of $45 million to Isomorphic, with potential performance-based milestones of up to $1.7 billion, excluding royalties. Novartis, on the other hand, will provide an initial payment of $37.5 million, along with additional funding for select research costs and performance-based incentives of up to $1.2 billion (excluding royalties) over time. 📈💰 🤖 Isomorphic Labs, founded in 2021 under Alphabet, utilizes DeepMind's AlphaFold 2 AI technology to predict protein structures in the human body. Despite its imperfections, the technology has shown immense promise in designing potential drugs, exemplified by a recent endeavor to treat hepatocellular carcinoma. 🧪👾 💡 Isomorphic's CEO, Demis Hassabis, expresses excitement about the partnerships, emphasizing the shared focus on advancing drug design approaches and cutting-edge science. 🌟 🌍 The collaboration aligns cutting-edge AI with medicinal chemistry, data science, and deep disease area expertise, opening new possibilities in AI-driven drug discovery. The potential for groundbreaking advancements in therapeutics is enormous! 🚀🔍 #DrugDiscovery #AIInHealthcare #BiopharmaInnovation #IsomorphicLabs #EliLilly #Novartis #AlphaFold2 #InnovativePartnerships 🧬💊🤖

What’s the major limiting factor for #AI/#ML today? And what’s the solution? The Financial Times gathered industry icons Roger M. Perlmutter (CEO, Eikon Therapeutics), Bari Kowal (SVP of Development Operations, Regeneron), and Thomas Miller (CEO and co-founder, Iambic Therapeutics), together with Benchling CEO Sajith Wickramasekara to share their predictions for the future of AI — and insights on how #pharma will get there. Check out their top takeaways from #FTPharma: https://lnkd.in/eSTGFY7g

An interesting article in today's Globe and Mail. AI hasn't lived up to the hype when it comes to pharmaceutical discovery. Bottom line: the problems are still too hard for current foundation models. https://lnkd.in/gBpTdiS7 Maybe the AI teams should start collaborating with the quantum teams working on the same problem: https://lnkd.in/gfm32ZHE

AI has moved from buzzword to transformative force, particularly in the realm of pharmaceuticals. As the industry grapples with the need for faster, more efficient drug development, AI has emerged not just as a tool of promise, but as a driver of real-world progress. From Bamlanivimab, an AI-assisted COVID-19 antibody treatment that received emergency use authorization in record time, to AI-designed candidates tackling complex conditions like idiopathic pulmonary fibrosis and obsessive-compulsive disorder, the intersection of AI and pharma is already reshaping the landscape. This is more than efficiency—it's about unlocking the potential for personalized medicine and addressing diseases long considered untreatable. The revolution isn't on the horizon—it’s here, and it’s redefining what’s possible. An insightful article by Micha Breakstone on AI - hype, hope or revolution. #AIinDrugDevelopment #PharmaInnovation #DrugDiscovery #FutureOfMedicine #HealthcareTransformation

Last year ended on news of some major AI - Pharma collaborations, and 2024 is starting strong on this front too, with 2 major deals announced with Alphabet Isomorphic partnering with both Eli Lilly and Novartis. Alphabets AI platform is able to predict protein structure and so could potentially speed up target discovery and compound construction. These deals are worth almost $ 3 billion combined, showing huge confidence in the positive effect AI could have on drug discovery. https://lnkd.in/eesvnfAu